Member Info for Moneymunch

Some very exciting new editions to Evgen's Scientific Advisory Board, including Prof Chalmers , Lead Investigator of SFX-01's Covid/ARDS trial at University of Dundee, along with Prof Rob Clarke, main man at University of Manchester looking after SFX-01's breat cancer programme with Dr Sacha Howell from Christie Oncology Foundation and Senior lecturer at Manchester, as well as Prof Phil Eaton who is involved in SFX-01's SHP2 development and also Prof Festuccia , which looks to be the main man behind SFX-01 for Glioblastoma, judging by some of his recent research in Italy.....all bodes well imho with so many high profile Academics involved with SFX-01's development and now all with a vested interest. Gla ;-)

Professor Claudio Festuccia - Università degli Studi dell'Aquila

L'Aquila, Italy

Glioblastoma multiform (GBM) is the most common primary glial tumor resulting in very low patient survival despite current extensive therapeutic efforts. Emerging evidence suggests that more effective treatments are required to overcome tumor heterogeneity, drug resistance and a complex tumor-supporting microenvironment. PBI-05204 is a specifically formulated botanical drug consisting of a modified supercritical C02 extract of Nerium oleander that has undergone both phase I and phase II clinical trials in the United States for treatment of patients with a variety of advanced cancers. The present study was designed to investigate the antitumor efficacy of this botanical drug against glioblastoma using both in vitro and in vivo cancer models as well as exploring efficacy against glioblastoma stem cells.

https://www.researchgate.net/profile/Claudio_Festuccia

http://evgen.com/wp-content/uploads/2021/02/EVG-Investor-presentation-February-2021.pdf

That's pretty interesting, Prof Chalmers Lead Investigator of the Covid-19 ARDS patient trial and the main man at University of Dundee is now been recruited to Evgen's Scientific Advisory board, as also has Prof Rob Clarke , the main man at University of Manchester looking after SFX-01's breast cancer programme...very timely and a show of extreme confidence imho...why have Prof Chalmers on board if they're weren't confident of good news on the Covid/Ards patient trials??? Gla :-)

http://evgen.com/wp-content/uploads/2021/02/EVG-Investor-presentation-February-2021.pdf

Here's the website for the trial....Good luck to you and old man. ;-)

https://star-covid19.com/

Courtesy of timbo on Advfn...Gla ;-)

There is now a new Investor slide deck available on the Evgen web site – well worth a look:

http://evgen.com/wp-content/uploads/2021/02/EVG-Investor-presentation-February-2021.pdf

A very nice late reported 780k buy at 10.05p along with a late reported 750k buy from yesterday at 10p which all bodes well and suggests that no one is getting back in volume at sub 10p and also suggests that the self-proclaimed clever b'stards are going to suffer if they're betting short...Gla holders...Contrary to the opinion of the know it all Gnome who has declared allegiance with the cretin who has declared that SFX-01/Sulforaphane science as a scam....certainly makes you wonder about credibility, motives and agenda...not to be trusted!!! Watch this space...multiple newsflow potential stacking UP!!!

Publication of the Scientific paper for SFX-01's Glioblastoma target coming soon , along with disclosure of the prominent European University and/or any other collaborators. Gla ;-)

Dr Huw Jones, Evgen CEO, commented: "We are excited by this compelling new data in a type of cancer which has severely limited therapeutic options for the patient. The positive tolerability profile of SFX-01 makes it a viable option for use in addition to current treatments. Our plan is to expand upon these pre-clinical data in this and new collaborations, and start the process of designing an appropriate Phase II clinical trial."

Ps not much profit likely for those betting short on the placing news, and not much profit likely on any forward selling of the placing shares with the sp sitting firmly in double figures....and looking strong for a rise....Gla holders...On and Up!!! :

Forecasts and valuation. We introduce new forecasts for 2021 and 2022 to reflect the costs of the CMC manufacturing scale-up activities, with year-end FY 2021 cash of c.£4.1m and a cash runway extending to year-end 2022.

We raise our SOTP rNPV target price to 29p to reflect the potential value in ARDS, Glioblastoma and Juvenescence.

Why would do that Superboy??? I don't filter posters regardless of the crap they post and I reply in kind....and strange how you suggest that offending posts are moved to page 2 etc, as that exactly what kingoaf has tried to do with the following...he obviously viewed this as being detrimental to his agenda and tried to swamp it with his subsequent desperate response. Gl :-)

Evgen Pharma raised £10m with up to £1.0m possible through an Open Offer to
fund/progress SFX-01 to key valuation inflection points that will provide a cash
runway until at least mid-2023.

LifeArc’s selection of SFX-01 and funding of a 300- patient Phase II/III trial in Acute Respiratory Distress Syndrome (ARDS), including COVID-19 patients, is a significant endorsement of SFX-01’s potential value, with near-term interim safety and futility data analysis expected in Q2 2021.

Additionally, Evgen should have potentially three Phase II-ready programmes by
year-end 2021, a platform technology that can translate into further investigatorled studies and a royalty stream from the application of Sulforadex as a delivery vehicle in non-pharma applications (up to $10.5m milestones plus royalties).

With this number of shots on goal, any one of which would be significant, we increase our SOTP rNPV-based target price to 29p with a bear/bull scenario of 15-52p.

Placing raised £10m with Open Offer (up to £1m) by way of the issue of up to 137.5m
shares at 8p, representing 50.0% of the enlarged equity.

Net funds will be used for

(i) additional preclinical studies,

(ii) a glioma clinical trial,

(iii) formulation and scale-up manufacturing for SFX-01 and

(iv) work to file an IND for SFX-01 in the US.

This will provide a cash runway to mid-2023 and through multiple valuation inflection points.

Novel molecule that has been shown to directly modulate at least three unrelated
mechanistic targets; Nrf2, STAT3 and more recently SHP2, resulting in Evgen targeting four diseases in cancer and inflammation, all with high unmet clinical needs.

Acute Respiratory Distress Syndrome (ARDS) +/- COVID-19. An interim safety/futility
analysis for the Phase II/III STAR trial is expected in Q2 2021, based on the first 100 patients, 89 of whom are enrolled. This should be a meaningful valuation inflection point.

Pre-clinical data updates in H1 2021 should provide the clarity for Evgen’s positioning of SFX-01 in breast cancer (eg. CDK4/6 resistant tumours), glioma (brain cancer) and a third undisclosed oncology indication and the evidence to partners for monetisation events.

Not without risk, but multiple shots on goal provide investors substantial upside
potential, given the number of opportunities that exist for monetising SFX-01 and
Sulforadex.

Average licence deal values within the areas of focus have generated upfront
payments and milestones of $11-35m and up to $325m, respectively, in addition to longterm royalty streams.

Lol Brain of Britain........Why would you particapate at 8p when you've just stated the science is a scam....you're a snide with a snide agenda.....;-)

Meanwhile.....the start of disclosure of the new shareholders Gla ;-)

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

Wed, 3rd Feb 2021 11:49

Intuitive Investments

Group PLC - closed-end investment company focused on life sciences sector - Acquires 2.2 million shares in Liverpool-based clinical stage drug development company Evgen Pharma PLC for 8 pence each, or GBP175,000 in total.

Acquisition was part of Evgen Pharma raising GBP10 million through an oversubscribed placing of 125 million shares at 8p each, the proceeds of which went towards "preclinical work for metastatic breast cancer, glioma and a further cancer indication yet to be announced" as well as as possible clinical trial in glioma patients.

This is Intuitive's fourth investment following its initial public offering in mid-December.

Why would i do that and how would you do that???

Jeez are you for real....at long last showing your true colours and snide agenda...you claimed yesterday that you had just sold out....ha ha ha....you sad little troll...ho ho ho....and as far your ridiculous juvenile statement that SFX-01 and Sulforaphane is a scam based science , you tell that to the patients who were involved in the breast cancer trials, where SFX-01 proved life changing for some....you are unbelievable and an utter disgrace.....you really don't have a clue , now get back under your stone you sad pathetic low life troll creature....Gla holders....the green light from the DSMB will be transformational for all concerned and add significant value....coming soon!!!! :-)

ps looks those that are betting short following the placing news are somewhat irked given that the sp sits at double figures and rising, and not the 8p they were expecting!!! ;-)

Finncap are looking rather bullish now and good news from the assessment of the DSMB on the first 100 patients recruited to the Covid/ARDS trial will see a mad dash for shares i reckon, including all of the placing shares, the majority of which will be tightly held imho...Gla holders......Evgen has the potential to be the Star Share of 2021..... ;-)

Evgen Pharma raised £10m with up to £1.0m possible through an Open Offer to
fund/progress SFX-01 to key valuation inflection points that will provide a cash
runway until at least mid-2023.

LifeArc’s selection of SFX-01 and funding of a 300- patient Phase II/III trial in Acute Respiratory Distress Syndrome (ARDS), including COVID-19 patients, is a significant endorsement of SFX-01’s potential value, with near-term interim safety and futility data analysis expected in Q2 2021.

Additionally, Evgen should have potentially three Phase II-ready programmes by
year-end 2021, a platform technology that can translate into further investigatorled studies and a royalty stream from the application of Sulforadex as a delivery vehicle in non-pharma applications (up to $10.5m milestones plus royalties).

With this number of shots on goal, any one of which would be significant, we increase our SOTP rNPV-based target price to 29p with a bear/bull scenario of 15-52p.

Placing raised £10m with Open Offer (up to £1m) by way of the issue of up to 137.5m
shares at 8p, representing 50.0% of the enlarged equity.

Net funds will be used for

(i) additional preclinical studies,

(ii) a glioma clinical trial,

(iii) formulation and scale-up manufacturing for SFX-01 and

(iv) work to file an IND for SFX-01 in the US.

This will provide a cash runway to mid-2023 and through multiple valuation inflection points.

Novel molecule that has been shown to directly modulate at least three unrelated
mechanistic targets; Nrf2, STAT3 and more recently SHP2, resulting in Evgen targeting four diseases in cancer and inflammation, all with high unmet clinical needs.

Acute Respiratory Distress Syndrome (ARDS) +/- COVID-19. An interim safety/futility
analysis for the Phase II/III STAR trial is expected in Q2 2021, based on the first 100 patients, 89 of whom are enrolled. This should be a meaningful valuation inflection point.

Pre-clinical data updates in H1 2021 should provide the clarity for Evgen’s positioning of SFX-01 in breast cancer (eg. CDK4/6 resistant tumours), glioma (brain cancer) and a third undisclosed oncology indication and the evidence to partners for monetisation events.

Not without risk, but multiple shots on goal provide investors substantial upside
potential, given the number of opportunities that exist for monetising SFX-01 and
Sulforadex.

Average licence deal values within the areas of focus have generated upfront
payments and milestones of $11-35m and up to $325m, respectively, in addition to longterm royalty streams.

Forecasts and valuation. We introduce new forecasts for 2021 and 2022 to reflect the costs of the CMC manufacturing scale-up activities, with year-end FY 2021 cash of c.£4.1m and a cash runway extending to year-end 2022.

We raise our SOTP rNPV target price to 29p to reflect the potential value in ARDS, Glioblastoma and Juvenescence.

Amazing prospects across multiple targets from a modest market cap, near term its all about SFX-01's Covid/ARDS patient trials....a positive assessment from the DSMB on the first 100 patients recruited will be massive news, and then multiple upside opportunies on the rest of the pipeline as good news rolls in, and then who knows what future opportunies Jim Mellon's £10.5m plus royalties licensing deal could provide, not just as a healthcare supplement as planned, but Evgen could devlop SFX-01 in the not too distant future as an anti-aging pharmaceutical now that there is strong evidence of Sulforaphane's anti-aging properties.....which undoubtedly will be big business and boomtime for those that succeed. Gl ;-)

.................

The European startups hacking the ageing process

The innovations that will extend our lives and delay the definite end.

25 January 2021

For the first time in human history, more people die from diseases that come as a consequence of old age — such as cancer and heart attacks — than infectious disease.

It is also the first time in history that humans are just starting to understand what actually makes us age, with a whole new science emerging around concepts like telomere attrition, epigenetic alterations and zombie cells.

Just a few months ago, scientists in Tel Aviv managed to actually reverse the ageing process for the first time ever.

These forces have led to a whole new ecosystem of early-stage biotech companies and VC investors with a bold mission: curing ageing. While still dominated by the US, this is an emerging force in European biotech as well.

We are living in the first iteration of humans on the planet that for the very first time understands, on a biochemical level, what makes us age.

https://sifted.eu/articles/european-longevity-startups/

The UK-US company Juvenescence is creating a network for longevity companies, scientists as well as AI specialists. It has so far invested in approximately 15 startups. The hopes to IPO in the coming year.

https://www.cnbc.com/2020/09/29/billionaire-jim-mellon-plans-to-take-life-extension-start-up-public.html

0  0 0

I posted this abstract by Jim Mellon recently amaretto, and ties in nicely with the news release and suggests some very good reasons why he set up the licensing deal with Evgen. Gl ;-)

Boom time - Jim Mellon

Longevity science will, I think, lead to the biggest stock market boom ever. It will make the recent medical cannabis boom look like nothing. For the first time in the history of mankind, the elixir of youth, the promise of living a longer life, will actually come true.

There is no one pill that you can take, but a combination of several pharmaceuticals, gene therapies, gene-related technology and treatments could extend your lifespan to 120.

I’m confident in predicting that the science of longevity will represent the biggest industry on the planet within 20 years, and that it will be affordable for everyone after about ten years of commercial exploitation.

Wear and tear

It is important to note that we’re not predestined to die. But as time goes on, the healing process of our body gets overwhelmed – wear and tear overwhelms repair.

We gradually go into a process called ‘loss of homeostasis’, which signals that our inner chemical balance is beginning to get upset, which eventually results in death.

There are some creatures out there, such as the C. elegans worm, which Google’s ageing company Calico is studying, that are made up of atoms and molecules just like us but don’t die naturally. Science has shown that the lifespan of a worm can be increased by up to 20 times using genetic manipulation.

Similar principles can apply to humans. There is a huge amount of bioscience activity in the UK, which is not widely known. There have been negative developments in the form of Neil Woodford’s investments and the government’s lack of funding in this area.

But now people like Sir John Bell are spearheading major efforts to build a home-grown industry. Increasingly, the nexus between VC universities and scientist-entrepreneurs that’s made the US so successful in this field is developing in the UK.

More Juvenescence employees are based here than anywhere else, so we’re very much British. It’s very important to us that the UK retains its status as the second major centre for life sciences in the world.

A very strong indication on why Jim Mellon bought in. Gla :-)

NEWS RELEASE 2-FEB-2021

Aging-US: Sulforaphane promotes C. elegans longevity and healthspan

"The results in this Aging-US research output, indicate that sulforaphane prolongs the lifespan and healthspan of C. elegans through insulin/IGF-1 signaling."

...............

Here, the authors asked whether sulforaphane may influence the lifespan and healthspan of C. elegans.

They found that sulforaphane significantly extends the lifespan of C. elegans and delays age-related phenotype changes.

The analysis of wild-type C. elegans and 9 mutant strains revealed that sulforaphane inhibited DAF-2 insulin/insulin receptor signaling and thereby increased DAF-16 nuclear translocation, resulting in the expression of the sod-3, mtl-1 and gst-4 target genes, which are known mediators of longevity in C. elegans.

The Herr Research Team concluded in their Aging-US Research Paper, "we are the first to report that sulforaphane prolongs the lifespan and increases the healthspan of C. elegans through the inhibition of DAF- 2/insulin/IGF-1 signaling and the activation of DAF- 16/FOXO nuclear transcription in C. elegans. Our study provides a promising hint regarding the suitability of sulforaphane as a new anti-aging drug. However, additional studies in invertebrates and mammalian model organisms are necessary to expand our findings."

https://www.eurekalert.org/pub_releases/2021-02/ijl-asp_1020221.php

Every chance Ontarget, give or take, and perhaps the very reason for the timing of the fundraise, to allow some major players in on the cheap before a potential stellar rise on good news, or £11m cash raised at 8p now, just incase the man from the DSMB says no....Gl :-)

89 patient already recruited to SFX-01's Covid/ARDS trial and so we could have 100 by end of this week, and then the Data Safety Monitoring Board will make their assessment, and so news highly possible in time for when the placing shares hit the market...the greenlight will be massive news and a huge endorsement and Huw has confirmed he will UPdate the market on how it's going and if it's working, and so positive news will take the market by storm, who know's maybe a repeat performance of SNG's phase 2 results...Grab 'em while you can imho...plenty more other news also likely in the coming weeks. Gla Holders...Evgen is now fully cashed for the foreseeable and have multiple opportunities for significant upside. :-)

Lol...smarter than kingoaf no doubt....easy to be out when you had no shares...ha ha ha ...Gl :-)